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Abstract 
The 2017 Nosology defines the new criteria for hypermobile Ehlers-Danlos syndrome (hEDS), which is 
now considered one end of a continuous spectrum encompassing isolated, non-syndromic joint 
hypermobility (JH) and hypermobility spectrum disorders (HSD).  Preliminary data indicate a link 
between JH and neurodevelopmental disorders and, in particular, developmental coordination 
disorder (DCD) in children. Assessing DCD in adults is difficult and the recently described functional 
difficulties questionnaire 9 (FDQ-9) is one of the few available tools. The aims of this study are to (i) 
validate FDQ-9 written in Italian and present normal values in 230 Italian controls; and (ii) explore the 
relationship of FDQ-9 with the brief pain inventory, composite autonomic symptom score 31, 
multidimensional fatigue inventory, attention deficit/hyperactivity disorder self-report version 1.1, 
and the SF-36 for quality of life in 105 Italian adults with hEDS/HSD. Validation of the FDQ-9 in Italian 
was carried out by translati n, cross-cultural adaptation and test/retest reliability analysis. A case-
control study was performed comparing the FDQ-9 outcome between 105 patients and 105 sex- and 
age-matched controls. Fifty-nine percent of the patients resulted positive compared to the 3.8% of 
controls (p-value <0.00001). In patients, FDQ-9 positive result associated with positive attention 
deficit/hyperactivity disorder self-report version 1.1 (OR = 4.04). Multivariate regression analysis 
comparing FDQ-9 with the other questionnaires demonstrated a strong association between positive 
FDQ-9 and the number of painful joints. Our preliminary data open wider management and 
therapeutic perspectives for coordination difficulties in hypermobile individuals. 
 
Keywords: coordination, dysautonomia, Ehlers-Danlos syndrome, joint hypermobility, quality of life, 
pain. 
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Introduction 
Hypermobile Ehlers-Danlos syndrome (hEDS) is probably the most common heritable connective 
tissue disorder and remains without known molecular bases (Tinkle et al., 2017). The 2017 
international classification of Ehlers-Danlos syndromes (EDS) and related disorders identifies stricter 
criteria for hEDS that is defined by the presence of generalized joint hypermobility (GJH) (criterion 1); 
two or more items among systemic involvement, positive family history and musculoskeletal 
involvement (criterion 2); and the exclusion of other hereditary and acquired connective tissue 
disorders (criterion 3) (Malfait et al., 2017). hEDS is also considered at one end of a continuous 
phenotypic spectrum which originates from isolated, non-syndromic joint hypermobility (JH) and 
passes through the recently defined hypermobility spectrum disorders (HSDs) (Castori et al., 2017). 
HSDs are terms used to defined all symptomatic individuals with JH who do not meet the new 
diagnostic criteria of hEDS (Castori & Hakim, 2017). 
One of the aims of the 2017 international classification was to solve the nosologic conundrum of 
the hEDS and the “old” joint hypermobility syndrome (JHS). Previous literature identified hEDS with 
the Villefranche criteria (Beighton, De Paepe, Steinmann, Tsipouras, & Wenstrup, 1998) and the JHS 
by the Brighton criteria (Grahame, Bird, & Child, 2000), a fact suggesting that the two disorders are 
distinct. One decade afterwards, a community of experts declared that the two disorders are 
indistinguishable on clinical grounds and, therefore, that they should be considered a single disorder 
(Tinkle et al., 2009). Now, hEDS is recognized by novel criteria, and the JHS is removed and 
incorporated within the HSDs, which do not overlap hEDS.   
In hEDS/HSD, quality of life (QoL) is frequently affected because of chronic pain and fatigue 
(Castori et al., 2012; Castori et al., 2013; Pacey, Tofts, Adams, Munns & Nicholson, 2015), and partly 
influenced by autonomic dysfunction (De Wandele et al., 2016). Co-morbidities are strong QoL 
determinants in hEDS/HSD, but the nature of their link with JH remains obscure. Fragmented data 
indicate that the association between JH and neurodevelopmental disorders is a potential field of 
interest. Daily practice on children with hEDS/HSD suggests a high rate of developmental motor and 
coordination disorders (Ghibellini, Brancati & Castori, 2015). In 2005, Adib, Davies, Grahame, Woo & 
Murray reported clumsiness and symptoms of poor coordination in 125 children with hEDS/HSD. In 
two studies, Kirby and colleagues suggested functional similarities between children with GJH or 
hEDS/HSD and those with developmental coordination disorder (DCD) (Kirby, Davies & Bryant, 2005; 
Kirby & Davies, 2007). Accordingly, GJH is more frequent in children with DCD (Jelsma, Geuze, Klerks, 
Niemeijer & Smits-Engelsman, 2013; Celletti et al., 2015) as well as in those with the commonly co-
morbid attention deficit and hyperactivity disorder (ADHD), compared to controls (Koldas Dogan, 
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Taner & Evcik,2011; Sinibaldi, Ursini & Castori, 2015). Nevertheless, DCD and ADHD are well-defined 
diagnoses only in the developmental age.  
The functional difficulties questionnaire 9 (FDQ-9) and ADHD self-report version 1.1 (ASRS-V1.1) 
are among the  few tools able to explore DCD- and ADHD-related symptoms in adults (Kessler et al., 
2005; Clark, Thomas, Khattab & Carr, 2013). The FDQ-9 was first presented in 2013 as a reliable tool 
for screening adults for a possible diagnosis of DCD. In the original paper, the general psychometric 
properties of FDQ-9 were investigated in 167 subjects from the general population and 90 patients 
who attended a hypermobility clinic (Clark, Thomas, Khattab & Carr, 2013). In a comparable sample 
of 90 JHS adults, the same group demonstrated a 56% prevalence of positive FDQ-9 screening, with a 
5.5 odds ratio compared to 113 healthy volunteers (Clark, Khattab & Carr, 2014). In a further work, 
the significance of FDQ-9 in relationship with the SMART wobbleboard was explored in healthy adults 
(Clark, Clark, Dorey & Williams, 2016). Nevertheless, studies exploring the relevance of this test in a 
clinical setting are still lacking.  
This work was aimed to (i) validate FDQ-9 in Italian and present its pattern in 230 Italian controls, 
and (ii) explore, for the first time, the relationships of FDQ-9 with the brief pain inventory (BPI) for 
pain, composite autonomic symptom score 31 (COMPASS-31) for autonomic symptoms, 
multidimensional fatigue inventory 20 (MFI-20) for fatigue, ASRS-V1.1 for ADHD features, and the 
Short Form-36 (SF-36) for QoL in 105 Italian adults with hEDS/HSD. Our study adds information for 
deciphering the complexities of body-mind connections in JH and related disorders.   
Patients and Methods 
Patients’ and controls’ selection 
Patients were enrolled from February 2016 to February 2017 in two expert Italian centers for JH 
and related disorders, i.e. the Medical Genetics Clinic of the San Camillo-Forlanini Hospital (Rome) 
and the Center for Diagnosis and Management of EDS and Hereditary Connective Tissue Disorders at 
the Spedali Civili University Hospital (Brescia). All patients underwent a systematic evaluation as 
previously described (Castori et al., 2014; Castori & Colombi, 2015). As data for this study were 
obtained before the publication of the 2017 International Classification, patients were originally 
selected according to the Villefranche and Brighton criteria (Beighton, De Paepe, Steinmann, 
Tsipouras & Wenstrup, 1998; Grahame, Bird & Child, 2000). Retrospectively, clinical data of selected 
patients were compared to the hEDS criteria of the 2017 International Classification and the 
alternative diagnoses of hEDS and HSD were annotated. In case of a suspected overlap with other 
acquired or hereditary connective tissue disorders, differential diagnosis extended to autoimmune 
rheumatologic screening, heart ultrasound, bone densitometry and other selected supplementary 
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ascertainments (i.e. ophthalmologic survey, brain and spine MRI) . When necessary, other sets of 
criteria, such as the revised Ghent criteria for Marfan syndrome (Loeys et al., 2010), were applied 
together with the use of appropriate molecular studies. No patients had evidence of intellectual 
disability or autism spectrum disorder.  
Italian controls were enrolled from colleagues and friends of the authors, as well as from the 
healthy individuals and their relatives attending prenatal screening at the San Camillo-Forlanini 
Hospital. Among these controls, three were bilingual native Italian speakers (see below). All clinical 
and controls gave their consent to the study, which is in accordance to the revised version of the 
Helsinki Declaration. This study was approved by the Local Ethics Committee (protocol no. 250/CE 
Lazio 1). 
Translation and cross-cultural adaptation of FDQ-9 
The FDQ-9 is a 9-items self-assessment instrument to indicate functional difficulties associated 
with DCD/dyspraxia, previously validated in English patients by Clark and colleagues (Clark, Thomas, 
Khattab & Carr, 2013). For each question, “very good” answers were calculated as 1 point, “good” as 
2 points, “poor” as 3 points, and “very poor” as 4 points. According to the original description of 
FDQ-9 (Clark, Thomas, Khattab & Carr, 2013), the cut-off above which functional difficulties 
impacting daily functional activities was fixed at 21.5, while a result ranging from 19 to 21 was 
considered borderline for difficulties impacting daily function. A score of 18 or below was considered 
negative for functional difficulties. 
Three bilingual native Italian speakers independently translated the FDQ-9 questionnaire into 
Italian (forward translation phase). Subsequently, a consensus was reached on a first preliminary 
Italian version based on the three translations. Next, two bilingual native English speakers 
retranslated the Italian version into English (back translation phase). Any inconsistency was resolved. 
Reproducibility, or test/retest reliability, was assessed using the questionnaires of 45 individuals (20 
hEDS/HSD and 25 controls) who completed the questionnaire and a second copy in a period of eight 
weeks after the first administration. 
Reference values of FDQ-9 in Italian controls 
Once translated and cross-culturally adapted, the Italian version of the FDQ-9 was administered 
to 230 Italian controls. Results from these 230 healthy individuals were used to trace the reference 
values of the FDQ-9 in the Italian general population.   
Psychometric evaluation of hEDS/HSD adults 
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One-hundred and five, directly evaluated hEDS/HSD adults underwent a series of psychometric 
tests after medical examination and diagnosis review during clinical follow-up at their reference 
medical center. Used tests included: FDQ-9 (see above for details), ASRS-V1.1,BPI, COMPASS-31, MFI-
20, and SF-36. From the 230 Italian controls, a sample of 105 healthy individuals was extracted, 
matched for age and sex with the hEDS/HSD patients’ group. This subsample was used as controls for 
the interpretation of the FDQ-9 results in hEDS/HSD patients. 
ASRS-V1.1 
The attentive-executive domain was evaluated in the patients’ sample by the ASRS-V1.1, which 
was originally developed for adults screening by the WHO together with revision of the WHO 
Composite International Diagnostic Interview (Kessler et al., 2005; Kessler et al., 2007). The ASRS-
V1.1 is a symptom checklist for the DSM-IV-TR criteria of ADHD (APA, 2000). The six questions of the 
part A of ASRS-V1.1 were found to be the most predictive for ADHD and were considered the basis 
for the ADHD screening in adults. ASRS-V1.1 was given to patients in its Italian version (freely 
downloadable at: https://www.aifa.it/documenti/ASRSV1.1.pdf).The sum of the six answers 
corresponds to how the adult patient has felt and acted in the last 6 months. The cut-off for 
suspecting ADHD in adults is currently 4 or more positive answers, calculated on the basis of 
frequency for each item. The results emerging from this evaluation may suggest the need for a more 
in-depth clinical analysis in order to confirm or discard the diagnosis, which remains difficult in 
adults. However, ASRS-V1.1 was calibrated to DSM-IV-TR criteria, which are narrower than the 
recently developed DSM-5 criteria (APA, 2013). The present work started before the publication of 
the DSM-5 updated version of this questionnaire, in which, however, the six questions of part A 
remain unchanged (Ustun et al., 2017). ASRS-V1.1 was never used in hEDS/HSD.  
BPI  
The Italian version of BPI was used to explore pain features in hEDS/HDS adults (Caraceni et al., 
1996). BPI is a self-administered multidimensional questionnaire for the evaluation of pain and 
analyzes four domains including history, location, intensity and interference with daily functions 
(Cleeland & Ryan, 1994). BPI can be used in adults and, consists of 13 items exploring time course of 
pain, pain extension, pain intensity, pain therapies, pain interference with motor and relational 
activities, and with sleeping and mood. For the present study, replies to questions no 3 to 6, 8 and 9 
were used as continuous variables. Concerning question no. 2 (homunculus for painful sites pointed 
by the patient with a pen), each painful point counted 1 and the sum was used as a continuous 
variable (“bodily pain”). In case of painful points clearly corresponding to joints a second continuous 
variable was extracted, specific for “joint pain”. No previous study on EDS has applied this test. 
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MFI-20 
MFI-20 was used for assessing fatigue in hEDS/HSD patients by using its Italian version (Jereczek-
Fossa et al., 2007). MFI-20 is a 20-item self-report scale that measures fatigue symptoms in adults. 
Items are grouped into five areas (general fatigue, physical fatigue, mental fatigue, reduced 
motivation and reduced activity) each composed of four items (Smets, Garssen, Bonke & De Haes, 
1995). All items require an evaluation on a 5-point scale, ranging from an answer in accordance with 
the question "yes, it's true" (= 1 point) to an answer of total disagreement "no, it's not true" (= 5 
points). For scoring, it is first necessary that items 2, 5, 9, 10, 13, 14, 16, 17, 18 and 19 are overturned 
(1 point  5 points, 2 points  4 points, 3 points  3 points , 4 points  2 points, 5 points  1 
point). Items compose the five areas as follows: items 1, 5, 12 and 16 refer to “general fatigue” 
(MFI20-GF); items 2, 8, 14 and 20 refer to “physical fatigue”(MFI20-PF); items 3, 6, 10 and 17 refer to 
“reduction of activities”(MFI20-RA); items 4, 9, 15 and 18 refer to “reduction of motivation”(MFI20-
RM); and items 7, 11, 13 and 19 refer to “mental fatigue”(MFI20-MF). Accordingly, all areas have a 
total subscale score ranging from 4 to 20. A higher score in each item and subscale is equivalent to a 
greater presence of related symptoms. The “general fatigue” subscale is considered the best 
indicator to assess fatigue with a single score (Smets, Garssen, Bonke & De Haes, 1995). MFI-20 was 
previously used in hEDS by our group in a single study (Celletti, Castori, La Torre & Camerota, 2013). 
COMPASS-31 
COMPASS-31 is a self-assessment instrument to evaluate dysautonomic symptoms based on 31 
items grouped in six autonomic domains, including 4 items for orthostatic intolerance (COMPASS31-
OI), 3 items for vasomotor (COMPASS31-VM),4 items for secretomotor (COMPASS31-SM), 12 items 
for gastrointestinal (COMPASS31-GI),3 items for bladder (COMPASS31-B), and 5 items for 
pupillomotor (COMPASS31-PM) functions (Sletten, Suarez, Low, Mandrekar & Singer, 2012). An 
Italian version of COMPASS-31 was previously validated and translated (Pierangeli et al., 2015). For 
scoring simple questions (e.g. presence vs absence), negative and positive answers were calculated 
as 0 and 1 points, respectively. Frequency of symptoms was scored as 0 points for rarely or never 
reported, 1 point for occasionally or sometimes reported, 2 points for frequently reported or 
reported “a lot of the time”, and 3 points for almost always or constantly reported. Severity of 
symptoms was calculated as 1 point for mild degree, 2 points for moderate degree, and 3 points for 
severe degree. For the time course of a symptom, 0 points were attributed for responses such as 
“gotten somewhat better”, “gotten much better”, “completely gone”, and “I have not had any of 
these symptoms”; 1 point for “stayed about the same”; 2 points for “gotten somewhat worse”; and 3 
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points for “gotten much worse”. Every domain is considered as single score derived by the sum of 
related items. No previous study on EDS applied COMPASS-31.  
SF-36 
Health status and particularly QoL were assessed by administering the SF-36 questionnaire to the 
patients’ sample. SF-36 has an Italian version (Apolone & Mosconi, 1998), which was previously used 
in EDS adults by our group and others (Castori, Camerota, Celletti, Grammatico & Padua, 2010; 
Rombaut, Malfait, Cools, De Paepe & Calders, 2010; Celletti, Castori, La Torre & Camerota, 2013). SF-
36 is a useful self-report 36-item questionnaire consisting of eight subscales that describe physical 
activity (PA), physical role limitations (PRL), physical pain (PP), general health (GH), vitality (V), social 
activity (SA), emotional role limitations (ERL), and mental health (MH) over the past four weeks. 
Every scale ranges from 0 to 100, with 0 indicating the negative lowest score and 100 indicating the 
positive highest score. These eight scales are then grouped in three areas, named physical health 
(PH=PA+PRL+PP), general health (GH+V) and psychological-emotional health (PEH=SA+ERL+MH). 
These scales were calculated using the algorithm freely available online and fully applicable to the 
Italian version of SF-36 (freely downloadable at: http://crc.marionegri.it/sf36/sf36v1ita.htm).  
Statistical methods 
Demographic and clinical characteristics were reported as medians with range and as frequencies 
and percentages for continuous and categorical variables, respectively. Test/retest reliability was 
measured by the intraclass correlation coefficient (ICC) and by the Pearson correlation coefficient(r).  
Group comparisons (case/control, positive/negative FDQ-9) were performed using Chi-square test 
and the non-parametric Mann-Whitney U test for categorical (e.g. positive/negative ASRS-V1.1) and 
continuous (i.e. scores at the various items, domains and areas of BPI, COMPASS-31, MFI-20, and SF-
36) variables, respectively. Multivariate logistic regression analysis was performed to assess the 
association between FDQ-9 (positive/negative) with BPI, COMPASS-31, MFI-20, and SF-36. Risks were 
reported as odds ratios (ORs). Two-sided P-values <0.05 were considered statistically significant. All 
the analyses were performed using SAS Release 9.4 (SAS Institute, Cary, NC) and SPSS software (SPSS 
version 21.0, SPSS Inc., Chicago, Illinois, USA). 
Results 
Demographic data 
One hundred and five adults with hEDS (Villefranche nosology) and/or JHS (Brighton criteria) were 
selected. Ninety-six were females and 9 males (female/male ratio: 10.6/1) with an age ranging from 
18 to 62 years (mean: 36.9 years, standard deviation: 12.08). Their diagnosis was revised 
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retrospectively, according to the 2017 International Classification of EDS and related disorders, and, 
hence, translated into the novel nosology of hEDS and HSD (Fig. 1). The distribution of the Beighton 
score in the patients’ sample is reported in Fig. 2. The 230 controls from the general population 
included 138 females and 92 males with an age range of 19 to 95 years (mean 38.43 years; standard 
deviation: 12.20). Compared to the 105 patients, the sex- and age-matched 105 controls were 96 
females and 9 males (p-value: 1.00) with an age range from 19 to 62 years (mean: 37.2 years, 
standard deviation: 12.31; p-value: 0.87).  
Validation of FDQ-9 in Italian 
The translation in Italian of the FDQ-9 questionnaire is reported in Table I. It reported an high 
degree of test/retest reliability both in the control group (n=20) as measured by the ICC = 0.965 and 
by the Pearson correlation coefficient r=0.934 (p<0.0001) and in the patients group  (n=25) as 
measured by the ICC = 0.966 and by the Pearson correlation coefficient r=0.935 (p<0.0001). 
Normal standards for FDQ-9 in Italian controls and results of FDQ-9 in hEDS/HSD adults and controls 
After translation and validation in Italian, the results of FDQ-9 in the 230 Italian controls were 
represented in a bar graph (Fig.3). In this non-clinical sample of 230 individuals, 6 (2.6%) resulted 
positive with a score above the cut-off (>21).  
Comparison of the FDQ-9 results between the 105 adults with hEDS/HSD and 105 matched 
controls is summarized in Fig. 4. The patterns of replies were significantly different between the 
groups for all the 9 items, with an excess of “positive” replies (“poor” and “very poor”) in the 
patients’ cohort. An overt excess of individuals with a score above the cut-off (>21) was registered 
among patients (62/105, 59.0%) compared to controls (4/105, 3.8%; χ
2
 = 74.33; p-value = <0.00001; 
Odds ratio = 36.41). We further analyzed the patients’ and controls’ samples by distinguishing 
between males and females, and by separating the samples in three categories as subsequently 
proposed by Clark, Clark, Dorey, & Williams, 2016 (i.e. ≤18 = no functional difficulties; 19-21 = at risk 
of having functional difficulties; >21 = with one or more functional difficulties). Results are 
summarized in Fig. 5. 
Relationships of the FDQ-9 with the other questionnaires in hEDS/HSD adults 
In the 105 adults with hEDS/HSD, the results of the FDQ-9 were compared to those of the other 
questionnaires (ASRS-V1.1, BPI, COMPASS-31, MFI-20 and SF-36). The comparison between the 
outcome to FDQ-9 (positive >21; negative ≤21)  and ASRS-V1.1 (positive ≥4; negative <4)  is reported 
in Fig. 6. Of the 105 hEDS/HSD, 55 (52.4%) resulted positive for the ASRS-V1.1 screening for ADHD. 
Positivity to the FDQ-9 questionnaire was significantly associated with a positive result to ASRS-V1.1 
in hEDS/HSD adults with a p-value of 0.0007 and an OR of 4.04 (95%IC = 3.26-4.82). Results of the 
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univariate analysis comparing the binary outcome to the FDQ-9 questionnaire (positive >21; negative 
≤21) and the various items, domains and areas of the BPI, MFI-20, COMPASS-31 and SF-36 
questionnaire (continuous variables) are reported in Table II. In summary, positive associations were 
identified for multiple items/domains/areas of BPI, COMPASS-31 and SF-36, while no significant 
finding occurred for MFI-20 (except for mental fatigue; MFI20-MF).The strongest associations (p-
value <0.002) were the number of painful joints (BPI), pain interference with work and sleep (BPI), 
symptoms of orthostatic intolerance and functional gastrointestinal symptoms (COMPASS-31), and 
effects on the psycho-emotional health (SF-36). Multivariate logistic regression analysis nullified all 
significant associations of the univariate analysis, except for the number of painful joints at the BPI 
(OR = 1.25, 95%CI = 1.06-1.47, p-value = 0.008).  
Discussion 
This work includes the validation of the FDQ-9 questionnaire in a second language and, for the 
first time, explores its impact on selected determinants of QoL. In particular, we realized a highly 
confident Italian translation of the FDQ-9 (Table I) which showed significantly high scores at the 
test/retest analysis. In addition, we applied FDQ-9 in a large control sample in order to present some 
normative values in the Italian population, which may be useful for future studies in different 
clinically relevant disorders potentially affecting coordination and manifesting related functional 
difficulties. According to previous studies on FDQ-9 (Clark, Thomas, Khattab & Carr, 2013; Clark, 
Khattab & Carr, 2014; Clark, Clark, Dorey, & Williams, 2016), we investigated the impact of this 
screening tool in patients with symptomatic JH, who are known to suffer from clinical manifestations 
potentially related to coordination difficulties, especially in their developmental years (Kirby, Davies 
& Bryant 2005; Kirdy & Davies, 2007; Piedimonte et al., 2018). Such data provides a foundation of 
evidence around JH and its potential clinical reverberations.    
The clinical boundaries of JH are broadening and the current nosology of EDS and related 
disorders extends to address a better classification of all patients with JH. Accordingly, individuals are 
now distinguished in subjects with (i) isolated, non-syndromic JH, (ii) well-defined syndromes with JH 
(also comprising all Mendelian disorders with JH as well as the newly defined hEDS), and (iii) HSDs 
(Castori et al. 2017; Castori & Hakim, 2017). At the same time, the existence of a continuous 
spectrum is accepted ranging from isolated, non-syndromic JH, to the various HSDs, to hEDS. This 
spectrum is the background family of phenotypes, in which patients with various forms of JH 
(symptomatic and asymptomatic, isolated and combined with other features), who are not 
associated with a specific genetic defect, are grouped. Isolated, non-syndromic JH and HSD are, in 
turn, subclassified according to the type of JH. In fact, patterns of JH include generalized JH, localized 
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JH, peripheral JH and historical JH on the basis of the Beighton score, 5-point questionnaire and 
presence/absence of JH in joints outside the Beighton score (Castori et al., 2017; Castori & Hakim, 
2017). This study focused on “symptomatic” patients belonging to the above described spectrum (i.e. 
patients affected by HSDs and hEDS). 
Within such a heterogeneous group of patients, who, in the past, were alternatively diagnosed 
according the “old” Brighton and Villefranche criteria, increasing evidence is drawing an unexpected 
association with a series of neuropsychiatric and neurodevelopmental attributes (Sinibaldi, Ursini & 
Castori, 2015; Ghibellini, Brancati & Castori, 2015; Baeza-Velasco, Sinibaldi & Castori, 2018). At the 
moment, the strongest association is between JH (usually, GJH) and anxiety disorders in adults 
(Bulbena et al., 2017). This prompted the Spanish group to propose the existence of a 
“neuroconnective phenotype” to define the heterogeneous pattern of psychosomatic reverberations 
of JH in adults (Bulbena, Pailhez, Bulbena-Cabré, Mallorquí-Bagué & Baeza-Velasco, 2015). 
Furthermore, JH is usually a congenital trait especially in individuals with generalized and/or bilateral 
forms of JH. This assumption has opened speculations on a possible “neurodevelopmental effect” of 
this trait in the developing child. Fragmented data suggest some overlap between the neuromuscular 
complaints of children with JH and those with DCD (Adib, Davies, Grahame, Woo & Murray, 2005; 
Kirby, Davies & Bryant, 2005; Kirby & Davies, 2007). We recently contributed to this issue by 
comparing 23 children affected by hEDS/HSD, classical EDS and Loeys-Dietz syndrome with a control 
group of children primarily ascertained for DCD (Piedimonte et al., 2018). In the “syndrome” group 
we found DCD, ADHD and learning disabilities in 30%, 13% and 22% of the cases, respectively. 
Conversely, in the DCD group, none had full characteristics of hEDS/HSD or other Mendelian 
disorders with JH; a fact which suggests a low rate of “syndromic diagnoses” in children primarily 
ascertained for DCD. The pattern of neuropsychiatric and neurodevelopmental attributes of children 
with syndromic DCD (first group) and whose with non-syndromic DCD (second group) significantly 
differed for the severity and range of somatic complaints and behavioral traits (Piedimonte et al., 
2018).  
In the present work, we formalized the known association between hEDS/HSD, DCD and ADHD in 
adults. Although the diagnosis of DCD and ADHD are difficult in the post-developmental age, the two 
applied screening tools, i.e. FDQ-9 and ASRS-V1.1, are considered reliable for a clinical suspicion of 
these conditions in adults. Accordingly, 59% and 52% of the sample resulted positive to FDQ-9 and 
ASRS-V1.1, respectively. This rate is likely to be an overestimation as the data relates to self-reported 
complaints. This is partly supported by the lower rate of proved diagnoses of DCD and ADHD in our 
previous “pediatric” study (Piedimonte et al., 2018). Nevertheless, our data demonstrate a high rate 
of complaints related to impaired coordination and attention in adults with hEDS/HSD. Interestingly, 
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the rate of 59% of “positive” FDQ-9 (i.e. >21) in the patients’ sample is comparable to the 56% in a 
previous work on 90 women with JHS by Clark, Khattab & Carr (2014). Our findings also mirrored 
what happens in the general pediatric population in which ADHD and DCD are common co-
morbidities. This is reflected by the results of the FDQ-9 and ASRS-V1.1, which are significantly 
associated in our clinical sample. The strong association between positive ASRS-V1.1 for ADHD and 
hEDS/HSD in our study confirms what has previously been explored by a Swedish retrospective 
nationwide study which showed that EDS seems to predispose to ADHD with a 5.6 relative risk 
(Cederlöf et al., 2016). These findings may be interpreted in line with the well-known impairment of 
proprioception and fear of falling in adults with JH or hEDS (Rombaut et al., 2011; Scheper et al., 
2017).  
  Multivariate logistic regression analysis showed a strong association between positive FDQ-9 and 
the number of painful joints in adults with hEDS/HSD. Interpretation of this finding is not clear-cut. 
However, some hypothesis can be put forward. First, a “clumsy” individual is more prone to soft-
tissue injuries, falls and joint traumas; a mechanism that might explain a high rate of post-traumatic 
joint pain in adults with JH and features of DCD. Available data also suggest a link between 
clumsiness and impaired proprioception in individuals with JH. Therefore, it is possible that subjects 
who are born with JH also present an impaired proprioception during their developmental age. It is 
presumed by the recent identification of significant impairment of postural controls in children with 
EDS (Lisi et al., 2017). This might facilitate the instauration of atypical motor schemes which 
predispose a lax joint to microtraumas and, hence, to the development of recurrent and chronic joint 
pain in children and adults. Therefore, our findings reinforce the link between the severity of 
functional difficulties and the rate of chronic widespread pain in hEDS/HSD, as previously 
hypothesized in JHS adults by Clark, Khattab & Carr (2014). In this perspective, in the hypermobile 
child, the presence of DCD might be predictive for the severity of joint pain (in terms of number of 
painful joints) in adulthood. This scenario is tempting for a possible preventive effect of 
proprioceptive improvement on joint pain in children with JH. 
Limitations of this study are different and may include: (i) patients were originally selected 
according to old criteria and their attribution to the novel diagnostic categories (hEDS and HSD) was 
carried out in retrospect with possibility of wrong subclassification in selected cases; (ii) the relatively 
limited number of patients may have limited our ability to appreciate statistically significant 
associations by multivariate logistic regression analysis; (iii) what was inferred by the use of 
psychometric tests was not supported by more objective investigations. Accordingly, this is an 
exploratory study aimed at raising attention of the neuropsychological attributes of JH, which may 
exist also beyond the developmental age and contribute to disability in adults.   
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In conclusion, our work validates the FDQ-9 test as a reliable screening tool for DCD in Italian 
adults. The patterns of replies to the 9 items of the FDQ-9 in 230 Italian controls can be used as 
normative values for future studies which will apply FDQ-9 in different Italian patients’ cohorts. We 
also demonstrated a high rate of a “likely” diagnosis of DCD in adults with hEDS/HSD. In these 
patients, positive FDQ-9 screening directly associates with a possible diagnosis of ADHD and number 
of painful joints. This work contributes to the understanding of the complex natural history of JH and 
the related hEDS/HSD, and open new scenarios for exploring the body-mind connections in these 
conditions.     
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Legends to Figures 
Figure 1 
Categorical diagnoses of the 105 enrolled patients. Comparison between the “old” nomenclature 
(Villefranche and Brighton criteria) and the 2017 International Classification of Ehlers-Danlos 
syndromes and related disorders. Sixty-nine patients met the Villefranche criteria (+/- Brighton 
criteria) and 36 the Brighton criteria only. Fifty-eight of those meeting the Villefranche criteria also 
met the 2017 criteria of hypermobile Ehlers-Danlos syndrome. The remaining eleven patients 
meeting the Villefranche criteria and all individuals respecting the Brighton criteria only were 
reclassified as hypermobility spectrum disorders.  
Figure 2 
Distribution of the Beighton score among the 105 patients with hypermobile Ehlers-Danlos 
syndrome/hypermobility spectrum disorders.  
Figure 3 
Patterns of replies to the nine items of the FDQ-9 in th  230 Italian controls. 
Figure 4 
Patterns of replies to the nine items of the FDQ-9 in the hypermobile Ehlers-Danlos 
syndrome/hypermobility spectrum disorder patients’ cohort and in the controls. Both groups are 
composed of 105 individuals (see text for more details). Significance of the differences is reported as 
p-values. hEDS/HSD = hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders.  
Figure 5 
Pattern of replies to the FDQ-9 questionnaire in the patients’ and controls’ groups. Replies are 
classified in ≤18 = no functional difficulties; 19-21 = at risk of having functional difficulties; >21 = with 
one or more functional difficulties. hEDS/HSD = hypermobile Ehlers-Danlos syndrome/hypermobility 
spectrum disorder.  
Figure 6 
Page 18 of 31
John Wiley & Sons, Inc.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
Relationship between the outcomes (positive vs negative = “at risk” vs “not at risk”) to the FDQ-9 and 
ASRS-V1.1 in the patients’ sample. 
 
 
Page 19 of 31
John Wiley & Sons, Inc.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Tables 
Table I. Original and Italian versions of the FDQ-9 questionnaire. 
Item 
no. 
FDQ-9 (Original Version) FDQ-9 (Italian Version) 
1 As a child, how good was your hand writing? Da bambino com'era la tua scrittura (n.d.a. scrittura a mano su carta)? 
2 As a child, were you good at team games that involved balls? i.e. football, 
netball, basketball 
Da bambino come te la cavavi con gli sport di squadra con la palla? 
3 As a child, how did others rate your coordination? Da bambino gli altri (genitori, insegnanti, amici) come consideravano la tua 
coordinazione? 
4 As an adult, how good are you at avoiding obstacles, like bumping into 
doors? 
Da adulto quanto riesci ad evitare gli ostacoli (p.e. attraversare una porta 
senza sbattere contro lo stipite/maniglia, evitare di urtare contro gli angoli 
di un tavolo)? 
5 As an adult, how good are you at organizing yourself? i.e. getting ready for 
work or for a meeting 
Da adulto quanto riesci ad organizzarti (p.e. prepararti in tempo per lavoro o 
per un incontro? 
6 As an adult, how good were you at catching a ball one handed? Da adulto quanto sei bravo a prendere al volo la palla (oppure,  oggetti di 
piccole dimensioni, ecc.)? 
7 As an adult, how good are you at balancing on a bike, in a bus or train, or on 
skis? 
Da adulto quanto sei capace a mantenere l'equilibrio in bici/sull'autobus/sul 
treno/in barca? 
8 As an adult, how good are you at using your hands i.e. to do jobs around the 
home, DIY, sewing or using scissors? 
Da adulto quanto sei bravo ad usare le mani, p.e. nel bricolage, nel taglio e 
cucito?  
9 As an adult, how good is your hand writing now? Da adulto com'é la tua scrittura  (n.d.a. scrittura a mano su carta)?  
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Table II. Results of the univariate analysis comparing FDQ-9 with BPI, MFI-20, COMPASS-31 and SF-
36 in 105 adults with hEDS/HSD.  
Items FDQ-9 negative (≤21; 
no. 43) 
 FDQ-9 positive (>21; 
no. 62) 
p-value 
 Median Range  Median Range  
Brief pain inventory       
Bodily pain (painful points) 5.0 0-21  10.0 1-24 0.002 
Joint pain (painful points) 2.0 0-12  5.5 0-12 <0.0001 
Intensity, maximum 6.0 0-10  8.0 3-10 0.006 
Intensity, minimum 3.0 0-10  4.0 0-9 0.106 
Intensity, mean 4.0 0-10  6.0 2-10 0.002 
Intensity, current 4.0 0-10  6.0 0-9 0.013 
Interference, GA 5.0 0-10  7.0 0-10 0.012 
Interference, mood 5.0 0-10  6.0 0-10 0.038 
Interference, rowing 5.0 0-10  7.0 0-10 0.005 
Interference, WA 5.0 0-10  8.0 0-10 <0.0001 
Interference, SR  3.0 0-10  5.0 0-10 0.003 
Interference, sleeping 5.0 0-10  8.0 0-10 0.001 
Interference, WTL 3.0 0-10  6.0 0-10 0.002 
Multidimesional fatigue 
inventory 20 
      
MFI20-GF 13.0 8-20  12.5 8-20 0.496 
MFI20-PF 15.0 6-20  14.0 8-20 0.497 
MFI20-RA 11.0 4-20  12.0 4-20 0.085 
MFI20-RM 13.0 6-20  14.0 8-20 0.503 
MFI20-MF 13.0 8-19  13.5 7-18 0.038 
Composite autonomic 
symptom score 31 
      
COMPASS31-OI 5.0 0-10  6.5 0-10 0.001 
COMPASS31-VM 2.0 0-6  3.0 0-6 0.016 
COMPASS31-SM 3.0 0-6  4.0 0-6 0.003 
COMPASS31-GI 10.0 0-20  14.0 1-21 0.001 
COMPASS31-B 1.0 0-6  3.0 0-9 0.003 
COMPASS31-PM 9.0 0-14  10.0 0-15 0.090 
Short form 36       
SF36-PA 60.0 0-100  45.0 5-100 0.004 
SF36-PRL 25.0 0-100  0.0 0-100 0.003 
SF36-PP 41.0 0-100  22.0 0-72 0.092 
SF36-GH 25.0 0-76  20.0 0-61 0.147 
SF36-V 40.0 0-80  22.50 5-85 0.005 
SF36-SA 50.0 0-100  37.0 0-100 0.004 
SF36-ERL 66.0 0-100  16.50 0-100 0.006 
SF36-MH 60.0 4-100  52.00 12-92 0.012 
SF36-PH 107.0 5-300  82.0 10-272 0.002 
SF36-GH+V 70.0 5-151  45.0 5-146 0.013 
SF36-PEH 183.0 16-300  112.0 16-292 0.001 
Significant p-values are in bold. The analysis was carried out by the Mann-Whitney non-parametric 
test. Abbreviations for the brief pain inventory (BPI): GA, general activity; SR, social relations; WA, 
working activity; WTL, will to live. Abbreviations for the multidimensional fatigue inventory 20 (MFI-
20): MFI20-GF, general fatigue; MFI20-PF, physical fatigue; MFI20-RA, reduction of activities; MFI20-
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RM, reduction of motivations; MFI20-MF, mental fatigue. Abbreviations for the composite 
autonomic symptom score 31: COMPASS31-B, bladder functions; COMPASS31-GI, gastrointestinal 
functions; COMPASS31-OI, orthostatic intolerance; COMPASS31-PM, pupillomotor functions; 
COMPASS31-SM, secretomotor functions; COMPASS31-VM, vasomotor functions. Abbreviations for 
the short-form 36 (SF-36): SF36-PA, physical activity; SF36-PRL, physical role limitations; SF36-PP, 
physical pain; SF36-GH, general health; SF36-V, vitality; SF36-SA, social activity; SF36-ERL, emotional 
role limitations; SF36-MH,mental health; SF36-PH,physical health; SF36-GH+V, general health plus 
vitality; SF36-PEH, psycho-emotional health. 
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Categorical diagnoses of the 105 enrolled patients. Comparison between the “old” nomenclature 
(Villefranche and Brighton criteria) and the 2017 International Classification of Ehlers-Danlos syndromes and 
related disorders. Sixty-nine patients met the Villefranche criteria (+/- Brighton criteria) and 36 the Brighton 
criteria only. Fifty-eight of those meeting the Villefranche criteria also met the 2017 criteria of hypermobile 
Ehlers-Danlos syndrome. The remaining eleven patients meeting the Villefranche criteria and all individuals 
respecting the Brighton criteria only were reclassified as hypermobility spectrum disorders.  
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Distribution of the Beighton score among the 105 patients with hypermobile Ehlers-Danlos 
syndrome/hypermobility spectrum disorders.  
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Patterns of replies to the nine items of the FDQ-9 in the 230 Italian controls.  
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Patterns of replies to the nine items of the FDQ-9 in the hypermobile Ehlers-Danlos syndrome/hypermobility 
spectrum disorder patients’ cohort and in the controls. Both groups are composed of 105 individuals (see 
text for more details). Significance of the differences is reported as p-values. hEDS/HSD = hypermobile 
Ehlers-Danlos syndrome/hypermobility spectrum disorders.  
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Pattern of replies to the FDQ-9 questionnaire in the patients’ and controls’ groups. Replies are classified in 
≤18 = no functional difficulties; 19-21 = at risk of having functional difficulties; >21 = with one or more 
functional difficulties. hEDS/HSD = hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder.  
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Relationship between the outcomes (positive vs negative = “at risk” vs “not at risk”) to the FDQ-9 and 
ASRS-V1.1 in the patients’ sample.  
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Ming T. Tsuang 
University of California, San Diego 
Harvard University 
Senior Editor, American Journal of Medical Genetics Part B Neuropsychiatric Genetics 
 
Stephen V. Faraone 
SUNY Upstate Medical University 
Editor, American Journal of Medical Genetics Part B Neuropsychiatric Genetics 
 
RE: replies to the intermediate revision for “Italian validation of the functional difficulties questionnaire (FDQ-9) and its 
correlation with major determinants of quality of life in adults with hypermobile Ehlers-Danlos syndrome/hypermobility 
spectrum disorder (NPG-18-0060)” 
 
 
 
Dear prof. Tsuang and prof. Faraone, 
 
I would be grateful to you if you will consider the revised version of the above mentioned paper for publication in the American 
Journal of Medical Genetics Part B Neuropsychiatric Genetics as a “Research Article”. 
 
Here you can find our replies to the reviewers’ comments. 
 
 
REVIEWER #1 
 
General comment. This is a well constructed study, the data appropriately analyzed, the literature appropriately considered, and the 
subject important to this area of Medicine. 
Reply. All authors thank this reviewer for her/his general consideration of the manuscript. 
 
Grammar/typing corrections. My comments are about typographical errors and a couple of sentences that seem incomplete. 
Presumably these will get picked up by the editorial team and lead author anyway but here is what I found (P = page , L = closest 
number on left though these do not match up well to the actual text lines): 
1. At several places there the misspelling "test/ritest" (P2 L20; P5 L41; P10 L25) 
2. I suggest INdistinguishable (modern English) rather than UNdistinguishable (P3, L30) 
3. At several places the second in list is numbered 'i' not 'ii' (P2 L14; P4 L26)  
4. P4 L53 to P5 L3 the sentence is not complete. 
5. P5 L14 the word 'according' should be 'accordance' 
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6. P5 L7 the word 'Ethic' should be 'Ethics' I think 
7. P6 L26-27 - the sentence I believe would read better as "The cut-off for suspecting ADHD in adults is currently 4 or more positive 
answers" 
8. P7 L9 - the word 'by' change to 'of' i.e. "...composed of four..." 
9. P7 L22 - the word 'has' to 'have' i.e. "...areas have..." 
10. P9 L13 - the italics should read RDQ-9 
11. P9 L30 - 'was' should be 'is' i.e. "...controls is summarized..." 
12. P9 L41 and P10 L4 - 'were' should be 'are' i.e. "The results are summarized in Fig. 5." and "...are reported in..." 
13. P9 L52 - 'at' should be 'for i.e. "...resulted positive for the..." 
14. P10 Senctence L7 to 12. I suggest this should read at the beginning as "The strongest associations (p-value <0.002) were:...", 
and that the comment about work should read "...pain interference with work and sleep,..." 
15. P10 L25 delete the 's' from the word controls 
16. P 10 L33 change 'of' to 'from' or 'with' i.e. "...to suffer from clinic..." 
17. P 11 L46 change the word 'suspect' to 'suspicion' 
18. P 12 L9 i think the words 'has' and 'been' are missing i.e. "...confirms what has previously been..." 
19. P12 L43-46 point (ii) - this needs rewording - perhaps "...may have limited our ability to appreciate statistically significant 
associations by mulivariate..." 
Reply. All corrections were included in the present version of the paper.  
 
 
REVIEWER #2 
 
General comment. The present article emphasizes the impact of developmental coordination disorders and impaired proprioception 
on adults' quality of life; […] 
Reply. All authors thank this reviewer for her/his general consideration of the manuscript. 
 
Comment. […] on this subject I would recommend citing the article by Lisi C et al. concerning impaired postural stability in EDS 
pediatric patients. In the paper a cross-sectional study matching a group of 12 cEDS and hEDS patients and a group of 12 healthy 
controls was performed, and was analized the displacement of the centre of pressure both with open and closed eyes using four 
parameters (standard deviation of antero-posterior excursion, standard deviation of latero-lateral excursion, sway path and sway 
area). The results showed significant impairment of postural control (specially of sway area) in patients' group.  
I would suggest to cite the article approximately at page 12, lines 24-30. 
Reply. The suggested reference was added in the manuscript by citing it exactly in the proposed paragraph.  
 
 
REVIEWER #3 
 
General comment. It's an interesting manuscript. 
Reply. All authors thank this reviewer for her/his general consideration of the manuscript. 
 
Comment 1. I have a principal question: which method have you used to validate the italian version of the FDQ-9 scale? 
Reply 1. The Italian version of the FDQ-9 was validated by a three-step analysis, including translation, cross-cultural adaptation and 
test/retest reliability analysis. In particular, the test/retest reliability analysis is a reproducibility test, at present, considered a highly 
confident tool for validating the translation of psychometric tests.  
  
Comment 2. Please add a table with the demographic caractheristics of the study group compared with the control group and specify 
if there are significant differences. 
Reply 2. Comparison among the patients’ and controls’ demographic characteristics (with p-values, all not significant) were reported 
on pages 9&10, as follows: “Ninety-six were females and 9 males (female/male ratio: 10.6/1) with an age ranging from 18 to 62 years 
(mean: 36.9 years, standard deviation: 12.08). Their diagnosis was revised retrospectively, according to the 2017 International 
Classification of EDS and related disorders, and, hence, translated into the novel nosology of hEDS and HSD (Fig. 1). The 
distribution of the Beighton score in the patients’ sample is reported in Fig. 2. The 230 controls from the general population included 
138 females and 92 males with an age range of 19 to 95 years (mean 38.43 years; standard deviation: 12.20). Compared to the 105 
patients, the sex- and age-matched 105 controls were 96 females and 9 males (p-value: 1.00) with an age range from 19 to 62 years 
(mean: 37.2 years, standard deviation: 12.31; p-value: 0.87)”. 
Given the very limited number of features to compare we decided to do not add a further table. Neverthless, we will surely add it in 
case the reviewer will consider this crucial for the quality of the paper.  
 
 
All contributors have contributed sufficiently to the intellectual content of this submission. They have also read and approved the 
submitted version of the manuscript.  
The authors declare that this work has not been published and/or submitted elsewhere, and that no conflict of interest exists 
concerning this manuscript.  
This is the first submission of this paper.  
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Yours faithfully, 
 
Marco Castori, MD, PhD 
Chief of the Division 
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